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wireless data transfer to the PC. Feasibility studies have 
been performed on DICOM images for meningioma and 
glioma brain tumors and neuroendocrine tumors (NET). The 
technique is in validation phase by testing it on “ex-vivo” 
specimen of patients affected by meningioma. 
Results: As first application we are investigating brain 
tumors. The goal is to apply the technique to glioma, but 
the first study case is meningioma being an efficient tracer 
(90Y-DOTATOC) already available for it. Preclinical tests 
and Monte Carlo simulations have estimated that in the 
case of meningioma to identify in 1s a residual of 0.1ml a 
radio-pharmaceutical activity of about 3MBq/kg must be 
administered to patient [2]. Similar studies were extended 
to NETs[3] Ex-vivo tests on meningioma showed excellent 
agreement between experimental and expected rates for 
lesions and healthy tissues: e.g. the bulk tumor showed 
signals of ~100cps, 0.2 ml residuals signals of ~40cps and 
healthy tissues of less than 5cps. 
Furthermore, exposure measurements confirmed the low 
level of radioactivity in the surgical environment (<1µSv/h 
at 10cm from patient abdomen). 
Conclusions: A very promising technique for RGS is under 
development. The low background would allow to extend 
RGS also to cases with a large uptake of nearby healthy 
organs where the established approach with γ radiation 
suffers due to the non-negligible background. 
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Purpose: Folate-receptor (FR)-targeted radioconjugates are 
promising for the imaging of a wide variety of tumor types 
[1]. So far, a number of folic acid conjugates have been 
developed for labeling with radiometals (e.g. 99mTc, 111In, 
68Ga) for SPECT and PET imaging [2]. The aim of this study 
was to synthesize a folate conjugate with an albumin-binding 
entity, which is known to increase the conjugate’s blood 
circulation time, and a NODAGA-chelator for 64Cu-labeling 
and [3]. 64Cu is a promising PET radionuclide for rf42 due to 
its excellent β+-energy (Eβ+=278 keV) and its reasonably long 
half-life (T1/2 = 12.7 h) [4]. The 64Cu-NODAGA-folate (64Cu-
rf42) was investigated in vitro and in vivo using mice bearing 
FR-positive tumor xenografts. 
Materials/methods: 64Cu was produced via the irradiation of, 
and subsequent chemical separation from, a Ni target at the 
research cyclotron at PSI. The synthesis of the NODAGA-
folate conjugate (rf42) was carried out in eight steps and the 
resulting product was characterized by HPLC, MS and NMR. 
The radioconjugate was prepared by incubation of rf42 with 
64CuCl2 in a mixture of HCl/Na-acetate (pH ~5.5) at 45°C for 
15 min. 64Cu-rf42 was investigated regarding its in vitro 
stability in PBS (pH 7.4) and in human plasma. FR-positive KB 
tumor cells were used for in vitro experiments. 
Biodistribution studies were carried out in KB tumor-bearing 
nude mice at 2 h, 4 h and 24 h post injection (p.i.) of 64Cu-
rf42. A small-animal scanner (Genisys8) was used for the 
PET/CT imaging studies 
Results: rf42 was synthesized with an overall yield of 5% and 
95% purity. The radiochemical purity of 64Cu-rf42 was >99% at 
a specific activity of 10 MBq/nmol. 64Cu-rf42 was stable 
(>95%) over a period of 24 h in buffer and plasma. Cell 
internalization studies showed high uptake of 64Cu-rf42, while 
co-incubation of cells with excess folic acid to block FRs 
reduced the uptake to less than 1%. In vivo, high 
accumulation of radioactivity was found in KB tumors (13.36 
± 0.82% IA/g) 2 h after injection of 64Cu-rf42. As a 
consequence of the enhanced blood circulation time of 64Cu-
rf42, due to its albumin-binding properties, the tumor uptake 
increased over time (16.20 ± 3.58% IA/g, 24 h p.i.). Relevant 
uptake of 64Cu-rf42 was also found in the kidneys, which also 
express the FR. This resulted in a tumor-to-kidney ratio of 
0.55 ± 0.11 at 24 h p.i. In non-targeted tissues undesired 
accumulation of radioactivity decreased over time. PET/CT 
imaging studies allowed excellent visualization of tumor 
xenografts up to 60 h p.i. of 64Cu-rf42.   
Conclusion: The novel folate-radioconjugate, 64Cu-rf42, was 
readily prepared and showed FR-specific accumulation in 
vitro and in vivo. The half-life of 64Cu is well suited to the 
enhanced circulation time of this novel albumin-binding 
conjugate. Based on the excellent PET images obtained from 
visualizing tumors in mice, 64Cu-rf42 may have the potential 
for future application in the clinics for diagnosis of FR-
positive tumors and monitoring tumor response after therapy. 
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High uncertainty in the Relative Biological Effectiveness 
(RBE) values of particle therapy beam, which are used in 
combination with the quantity absorbed dose in 
radiotherapy, together with the increase in the number of 
particle therapy centres worldwide (58 in operation, 51 
proposed) necessitate a better understating of the biological 
effect of such modalities. The present novel study is part of 
